Hepatitis C Update and Expanding the Role of Primary Care

Article Figures & Data

Table 1.

Comparison of Recommended First-Line Direct-Acting Antiviral Regimens Used for Treatment of Treatment-Naïve Hepatitis C Patients, as of 1/1/2018

Name of Direct-Acting Antiviral Combination Product	Ledipasvir/Sofosbuvir (Harvoni), 90 to 400 mg	Velpatasvir/Sofosbuvir (Epclusa), 100 to 400 mg	Grazoprevir/Elbasvir (Zepatier), 50 to 100 mg	Glecaprevir/Pibrentasvir (Mavyret), 100 to 40 mg
Drug classes	NS5a-NS5b	NS5a-NS5b	NS3/4-NS5a	NS3/4-NS5a
Genotypes	1, 4, 5, 6	1, 2, 3, 4, 5, 6	1 and 4	1, 2, 3, 4, 5, 6
Dosage for noncirrhotic patients	1 tablet daily for 12 weeks^*	1 tablet daily for 12 weeks	1 tablet daily for 12 weeks^†	3 tablets daily for 8 weeks
Can be used in patients with severe CKD (CrCl <30 mL/min)	No	No	Yes	Yes
Cost estimate^‡	$96,000	$75,000	$55,500	$27,000

↵* Genotype 1 patients who are non-black, HIV-uninfected, and whose HIV RNA level is <6 million IU/mL may be treated with 8 weeks of Ledipasvir/Sofosbuvir
↵† For Genotype 1a patients without baseline NS5a resistance associated substitutions for elbasvir (positions 28, 30, 31, or 93), all Genotype 1b patients, and all Genotype 4 patients.
↵‡ Estimated retail price of treatment based on information obtained at http://www.goodrx.com (accessed January 4, 2018).